ReviewTherapeutic advances in gastroenterology2014
Colonic smooth muscle cells and colonic motility patterns as a target for irritable bowel syndrome therapy: mechanisms of action of otilonium bromide.
Review in Therapeutic advances in gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 21 citations in OpenAlex.
- Otilonium bromide exhibits novel antifungal activity againstVirulence · 2026Article
- Intestinal muscularis in health and disease.Communications biology · 2026Review
- Multicenter Real-World Observational Study of Pargeverine/Lysine Clonixinate in Acute Visceral Colicky Pain.Medicina (Kaunas, Lithuania) · 2026Observational
- CARD14 signaling in intestinal epithelial cells induces intestinal inflammation and intestinal transit delay.EMBO molecular medicine · 2025Article
- Otilonium Bromide Prevents Cholinergic Changes in the Distal Colon Induced by Chronic Water Avoidance Stress, a Rat Model of Irritable Bowel Syndrome.International journal of molecular sciences · 2023Article
- The effects ofPeerJ · 2022Article
- Interaction between the Gut Microbiota and Intestinal Motility.Evidence-based complementary and alternative medicine : eCAM · 2022Review
- Neuromechanism of acupuncture regulating gastrointestinal motility.World journal of gastroenterology · 2020Review
- Article
- Repeated otilonium bromide administration prevents neurotransmitter changes in colon of rats underwent to wrap restraint stress.Journal of cellular and molecular medicine · 2017Article
- Efficacy of otilonium bromide in irritable bowel syndrome: a pooled analysis.Therapeutic advances in gastroenterology · 2017Article
- Electroacupuncture at ST25 inhibits jejunal motility: Role of sympathetic pathways and TRPV1.World journal of gastroenterology · 2016Article
- Changes in nitrergic and tachykininergic pathways in rat proximal colon in response to chronic treatment with otilonium bromide.Neurogastroenterology and motility · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Otilonium bromide (OB) is a spasmolytic compound of the family of quaternary ammonium derivatives and has been successfully used in the treatment of patients with irritable bowel syndrome (IBS) due to its specific pharmacodynamic effects on motility patterns in the human colon and the contractility of colonic smooth muscle cells. This article examines how. OB inhibits the main patterns of human sigmoid motility in vitro, which are spontaneous rhythmic phasic contractions, smooth muscle tone, contractions induced by stimulation of excitatory motor neurons and contractions induced by direct effect of excitatory neurotransmitters. It does this mainly by blocking calcium influx through L-type calcium channels and interfering with mobilization of cellular calcium required for smooth muscle contraction, thereby limiting excessive intestinal contractility and abdominal cramping. OB also inhibits T-type calcium channels and muscarinic responses. Finally, OB inhibits tachykinin receptors on smooth muscle and primary afferent neurons which may have the joint effect of reducing motility and abdominal pain. All these mechanisms mediate the therapeutic effects of OB in patients with IBS and might be useful in patients with other spastic colonic motility disorders such as diverticular disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.